Clinical Trials Browser

Phase 1 × Lymphoma, B-Cell, Marginal Zone × Specimen Handling × Clear all

NCT06191887 2026-02-13

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01955499 2025-11-10

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

39 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06712810 2025-10-10

Q702 for the Treatment of Patients With Hematologic Malignancies

Phase 1 Recruiting

46 enrolled

DermatologicLymphoidMyeloidOther hematologic neoplasmSarcoma

Blastic Plasmacytoid Dendritic Cell Neoplasm, Histiocytosis, Langerhans-Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Erdheim-Chester Disease, Dendritic Cell Sarcoma, Interdigitating, Histiocytic Sarcoma, Primary Myelofibrosis

NCT06859008 2025-08-05

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

37 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell